INS and obesity disorder: Interestingly, whereas the variants of PST in the C-terminal half of the molecule at 287 (Glu287Arg) and at 297 (Gly297Ser) enhance anti-insulin effects and elevate plasma glucose by inhibition of glucose uptake and stimulation of gluconeogenic effects, experimental deletion of the three N-terminal amino acids Pro–Glu–Gly on human WT-PST demonstrated the opposite effects by reducing plasma glucose level and hepatic gluconeogenesis in a rodent model of obesity (64).